The study is now in the phase II expansion phase.

        Inclusion Criteria for phase II:

          -  The target tumor is limited to neuroblastoma and the diagnosis should be
             histologically verified.

          -  Patients must have refractory or recurrent malignancy; patient's current disease state
             must be one for which no known curative therapy is available;

          -  Patients should not receive any other experimental or phase 1 therapy within 3 weeks
             prior to study enrollment and monoclonal antibody therapy within 6 weeks

          -  To be eligible for phase I study patients should have primary refractory or relapsed
             disease as evidenced by:

               -  Local tumor recurrence measurable on CT or magnetic resonance imaging (MRI) scans
                  with or without metastatic lesions

               -  Refractory bone marrow involvement in patients with NB

               -  NB with MIBG-positive skeletal lesions

          -  The presence of radiographically measurable disease immediately prior to start of
             Phase I immunotherapy is not an eligibility requirement in the following situations:

               -  In patients with NB who have documented bone marrow (BM) involvement;

               -  In patients with NB who have MIBG-positive bony lesion(s);

          -  An additional eligibility requirement for phase II study includes the presence of
             radiographically measurable disease with the exception of MIBG-positive NB or NB with
             bone marrow involvement:

          -  Patients must have a Lansky or Karnofsky performance status score of >= 70

          -  Patients must have fully recovered from the acute toxic effects of all prior
             chemotherapy, immunotherapy, or radiotherapy

               -  Myelosuppressive chemotherapy: must not have received within 3 weeks of starting
                  immunotherapy (IT)

               -  Hematopoietic growth factors: at least 7 days since the last dose of growth
                  factor therapy

               -  Immunotherapy: at least 6 weeks must have elapsed since prior therapy that
                  includes a monoclonal antibody

          -  Normal organ function

          -  All patients or their parents or legal guardians must sign a written informed consent;
             assent, when appropriate, will be obtained according to institutional guidelines

          -  All institutional, Food and Drug Administration (FDA), and National Cancer Institute
             (NCI) requirements for human studies must be met

        Exclusion Criteria:

          -  Patients who are pregnant or breast-feeding are not eligible for this study; negative
             pregnancy tests must be obtained in girls who are postmenarchal; males or females of
             reproductive potential may not participate unless they have agreed to use an effective
             contraceptive method for the duration of study therapy and for 3 months after the last
             dose of GD2Bi-aATC; breastfeeding women should be excluded

          -  Patients who have an uncontrolled infection are not eligible

          -  Patients who in the opinion of the investigator may not be able to comply with the
             safety monitoring requirements of the study are not eligible